Step 1 topics → Musculoskeletal, Skin, and Connective Tissue → Corticosteroids (Systemic and Topical)

Corticosteroids (Systemic and Topical)

USMLE Step 1 trap: Confuses corticosteroid genomic mechanism with direct receptor antagonism at the cell surface. Corticosteroids act via intracellular glucocorticoid receptors that translocate to the nucleus and alter gene transcription, suppressing NF-κB and reducing cytokine/phospholipase A2 production.

Corticosteroids are one of the highest-yield drug classes on USMLE Step 1 — they show up in MSK, derm, pulm, rheum, and pharm vignettes. The core concept is that these drugs mimic endogenous cortisol and work through a genomic mechanism: binding intracellular glucocorticoid receptors, translocating to the nucleus, and altering gene transcription. That last part is what students consistently miss — this is not receptor antagonism at the cell surface, it's transcriptional reprogramming that downstream suppresses NF-κB, phospholipase A2, and the entire cytokine cascade. Understanding this mechanism explains both the drug's power and its delay of onset.

The exam tests corticosteroids from three angles: mechanism (how do they actually work?), chronic toxicity (what happens to a patient on prednisone for years?), and topical potency selection (which steroid strength do you pick for which body site?). Vignettes will describe a patient on chronic steroids presenting with a new problem — your job is to recognize whether that problem is a predictable adverse effect (osteoporosis, cushingoid features, steroid myopathy, HPA suppression) or a management pitfall (don't abruptly stop, don't use high-potency steroids on the face). The toxicity and withdrawal questions are where students lose the most points.

What makes this topic tricky is that students memorize the side effect list without understanding the underlying physiology, so they underestimate how dangerous abrupt withdrawal is and overestimate where high-potency topical agents are safe. USMLE Step 1 loves asking about the patient who's been on prednisone for six months and now needs surgery or stops taking it — recognizing adrenal crisis risk requires knowing that chronic exogenous glucocorticoids suppress the HPA axis and cause adrenal atrophy. Similarly, topical potency questions hinge on body-site pharmacokinetics, not just disease severity.

From real student decks
89%have cards covering this topic
65%have mature cards

Common misconceptions

Common mistake
Wrong: Corticosteroids act primarily by directly blocking cytokine receptors on the cell surface.
Right: Corticosteroids act via intracellular glucocorticoid receptors that translocate to the nucleus and alter gene transcription, suppressing NF-κB and reducing cytokine/phospholipase A2 production.
Corticosteroids do not block cytokine receptors on the cell surface — that's the mechanism of biologics like tocilizumab or monoclonal antibodies. Corticosteroids are lipid-soluble and diffuse across the cell membrane to bind cytoplasmic glucocorticoid receptors. The receptor-drug complex then translocates into the nucleus and directly alters gene transcription, including suppression of NF-κB (which drives cytokine production) and upregulation of lipocortin (which inhibits phospholipase A2, blocking arachidonic acid release). This genomic mechanism is why effects have a delay of hours and why chronic use causes widespread systemic consequences — you're reprogramming gene expression, not just blocking a single surface receptor.
Common mistake
Wrong: Abrupt discontinuation of chronic corticosteroids causes only mild rebound inflammation.
Right: Chronic exogenous corticosteroids suppress the HPA axis, causing adrenal atrophy; abrupt discontinuation can precipitate life-threatening adrenal crisis (Addisonian crisis).
The danger of abrupt steroid withdrawal is not just rebound inflammation — it's potentially fatal adrenal crisis. When exogenous glucocorticoids are given chronically, negative feedback suppresses ACTH release from the pituitary, which causes the adrenal cortex to atrophy from disuse. After months of this, the adrenal glands cannot rapidly produce cortisol on their own. If steroids are stopped abruptly — especially during physiological stress like surgery or illness — the patient cannot mount a cortisol response and can develop hypotension, hyponatremia, hyperkalemia, and shock. Always taper chronic steroids and provide stress-dose hydrocortisone perioperatively.
Common mistake
Wrong: High-potency topical steroids are appropriate for facial or intertriginous skin conditions.
Right: High-potency topical steroids should be avoided on the face and intertriginous areas due to risk of skin atrophy, striae, and systemic absorption; low-potency agents are preferred there.
Potency selection is not just about disease severity — it's about the pharmacokinetics of the skin at the application site. Facial skin and intertriginous skin (axilla, groin, under the breasts) are thin, occluded, and absorb topical steroids at much higher rates than thick truncal or palmar skin. Applying high-potency agents like clobetasol to these areas causes local skin atrophy, telangiectasias, striae, and perioral dermatitis, plus significantly more systemic absorption. Reserve high-potency steroids for thick plaques on the body (palms, soles, thick scalp plaques); always use low-potency agents (hydrocortisone 1-2.5%) on the face, eyelids, and skin folds regardless of the diagnosis.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the genomic mechanism of corticosteroids: they bind intracellular glucocorticoid receptors that translocate to the nucleus, suppressing NF-κB and reducing transcription of inflammatory mediators like cytokines and phospholipase A2 — this is not surface receptor blockade.
  2. Recognize the full spectrum of chronic systemic steroid toxicities: osteoporosis, Cushingoid features (moon face, buffalo hump, central obesity), hyperglycemia, hypertension, steroid myopathy (proximal weakness), immunosuppression, cataracts, avascular necrosis of the femoral head, and psychiatric effects.
  3. Understand HPA axis suppression from chronic steroid use: abrupt discontinuation after prolonged therapy can precipitate adrenal crisis — know why this happens (adrenal atrophy from feedback suppression) and how to manage it (taper, stress-dose steroids perioperatively).
  4. Apply topical corticosteroid potency classes to clinical scenarios: high-potency agents (e.g., clobetasol) are for thick skin plaques on the body; low-potency agents (e.g., hydrocortisone 1%) are required for the face, eyelids, and intertriginous areas to avoid skin atrophy, striae, and excess systemic absorption.

Can you avoid these mistakes?

A patient with rheumatoid arthritis has been on prednisone 20 mg daily for 8 months. She is scheduled for elective hip replacement surgery and her surgeon tells her to stop all medications the morning of surgery. What is the most serious risk of this approach, and what should be done instead?
A medical student claims that corticosteroids reduce inflammation by binding to cytokine receptors on immune cell surfaces, preventing cytokine signaling. What is wrong with this model, and what is the correct mechanism?
A 35-year-old woman presents with seborrheic dermatitis affecting her nasolabial folds and eyebrows. You prescribe a topical corticosteroid. Should you use clobetasol 0.05% or hydrocortisone 1%? Explain why the site of application matters beyond just choosing based on disease severity.
A patient on chronic prednisone develops new proximal muscle weakness — he has difficulty rising from a chair and climbing stairs, but his CK is normal. What is the likely diagnosis, and how does it differ from inflammatory myositis on labs and biopsy?

Related topics

Bone Cells and Matrix Endochondral vs Membranous Ossification Fracture Healing Stages Compartment Syndrome

See how your Anki deck covers this topic.

Upload your deck for a free audit →